CAMBRIDGE, Mass. A biopharmaceutical company specializing in the treatment of cancer announced the appointment of its new chief medical officer.
Aveo Pharmaceuticals appointed William J. Slichenmyer, as chief medical officer. Prior to joining Aveo, Slichenmyer, a 15-year industry veteran, he served as chief medical officer at Merrimack Pharmaceuticals, where he led the development of novel protein-based therapeutics for patients with cancer and autoimmune diseases.
Additionally, Robert C. Young was elected to Aveo's board of directors. Young is the president of RCY Medicine and former chancellor of Fox Chase Cancer Center in Philadelphia, Pa.
“We are thrilled to announce these strategic additions to our management team and board of directors as they position the company for our next phase of growth and further support us as we achieve steps toward our goal of building a fully-integrated oncology company,” said Tuan Ha-Ngoc, president and CEO of Aveo.